来源:因美纳2025年7月30日,因美纳公司(纳斯达克股票代码:ILMN)宣布,正式推出其旗舰款癌症研究检测方案 TruSight™ Oncology 500 的新一代版本,该检测方案支持开展全景变异分析(CGP)。全景变异分析是加速精准医疗可及性的重要工具,通过提供肿瘤分子特征图谱,助力实验室推进治疗方案选择和临床试验入组的研究。TruSight Oncology 500 version 2(...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.